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ABSTRACT
The boronated aromatic amino acids were shown to be potent hypolipidemic agents in mice lowering both
serum cholesterol and triglycerides aer 16 days. Selective compounds were as effective as the clinical
standards. Furthermore, the compounds were effective anti-inflammatory agents reducing local and central pain
as well as suppressing LPS induced endotoxic shock in mice. These agents inhibited lysosomal and
proteolytic enzymes of the liver and macrophages as a part of their mechanism of action.
INTRODUCTION
L-Phenylalanine, tyrosine, proline, histidine and tryptophan boronated derivatives as well as their metal
complexes have recently been shown to be potent antineoplastic or cytotoxic agents [1-6]. Previously with the
boron analogues of o-amino acids, i.e amine-carboxyboranes, heterocyclic amine boranes and 2’-
deoxynucleoside boranes other biological activities, e.g. hypolipidemic [7-13], antiarthritic, antiinflammatory,
antiosteoporoeous[14-19] have been demonstrated in rodents. The present investigation involved the
examination of boronated aromatic amino acids as potent hypolipidemic or anti-inflammatory agents in mice
at 8 mg/kg, I.P.
MATERIAL AND METHODS
Source of Compounds
All of the boronated aromatic amino acids or their metal complexes were synthesized and published
previously: 2-[(N-methylmethanamine)methyl-carbonyl]amino-3-phenyl-methyl propanoate 3 [6], ], (N,N-
dimethylmethanamine)dihydr[[[-(phenymethy)-2-methxy-2-xethy]amin]carbny]brn 4 [3], (N-
methylmethanamide)dihydro[[[ 1-(phenylmethyl)-2-methoxy-2-oxoethyl]amino]carbonyl]boron 5 [3];
(methanamine)dihydr[[[-phenymethy)-2-methyamin-2-xethy]amin]carbny]brn 6 [3], sodium -2-
(N,N-dimethylmethanamine)dihydroboron-carbonyl]amino-3-phenyl-propanoate 7 [5], tetrakis-{2-[N,N-
dimethylmethanamine)dihydroboron-carbonyl]amino-3-phenyl-propyl carboxylate}-bis-{2-[N,N-dimethyl-
methanamine)dihydroboron-carbonyl]amino-3-phenyl-propanoate}dicopper(II) 8 [5], (ammonia)dihydro[[[1-
(phenylmethyl)-2-methoxy-2-oxoethyl]amino]carbonyl] boron 9 [3 ], (N,N-dimethyl-methan-
amine)dihydro[[[ 1-(4-hydroxyphenyl)-methyl)-2-methoxy-2-oxoethyl]amino]carbonyl]boron 10 [3], (N-
methymethanamide)dihydr[[-[(4-hydrxypheny)-methy]-2-methxy-2-xethy]amin]carbny]brn 11
[3], (methanamine)dihydr[[-[(4-hydrxypheny)-methyamin-2-xethy]amin]carbny]brn 12 [3],
(ammonia)dihydro[[[ 1-(4-hydroxyphenyl)-methyl)-2-amino-2-oxoethyl]amino]carbonyl]boron 13 [3 ],
(cyano)dihydro[[ 1-(phenylmethyl)-2-amino-2-oxoethyl]amino]boron 14 [3 ], N-acetyl-4-
boronphenylalanylphenylalanine methyl ester 15 [2], N-acetyl-4-boronphenylalanyltyrosine methyl ester 16
[2], N-[(trimethylamineboryl)-carbonyl]-L-histidinemethyl ester 17 [4], N-[(trimethylamineboryl)-carbonyl]L-
tryphophan methyl ester 18 [4]. N-[(trimethylamineboryl)-carbonyl] -L-proline methyl ester 19 [2]. L-
phenylalanine 1 [Alrich Chemical Co.], L-phenylalanine methyl ester hydrochloride 2 [Aldrich Chemical,
Co.] were purchased commercially.
All substrates, co-factors and standard drugs were purchased from Sigma Chemical Co.
Pharmacological Methods
Hypolipidemic Assay.
CF male mice (28g) were administered drugs prepared in 1% carboxymethylcellulose [CMC] by
homogenization at 8 mg/kg/day, I.P. for 16 days. On days 9 and 16 the mice were bled from the tail vein
collected in capillary tubes which were centrifuged at 3000 x g for 3 rain. Total cholesterol was determined on
the serum using the Libermann-Burchard method [20] determined at 620 nm. Serum triglycerides were
determined on day 16 using commerical kits from Sigma Chemical, Co. read at 580 nm. Clofibrate was
determined at 150 mg/kg/day I.P. and lovastatin was determined at 8 mg/kg/day I.P., which are the drugs’
standard therapeutic doses.
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Figure Structures of Aromatic Boronated Amino Acids
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Anti-inflammatory Activity.
CF male mice (-25 g) were administered drugs at 8 mg/kg in 1% CMC I.P, at 3 h and again 30 min prior to
the injection in 0.2 ml of carrageenan in 0.9% saline into the plantar surface of the high hind foot. Saline was
injected into the left hind foot which served as the standard base line. Atier 3 h both feet were excised at the
tibiolarsal (ankle) joint according to the modified method of Winter et al.[21], resulting in 84 mg increase in
the paw weight of the control mice.
Local Analgesic Activity-Writhing Reflex.
Male CF1 male mice (-25g) were administered test drugs at 8 mg/kg I.P. 20 min prior to the administration
of 0.5 ml of 0.6% acetic acid, I.P. [22]. Aler 5 min the number of stretches, characterized by repeated
contractions of the abdominal musculature accompanied by extension of the hind limbs for the next 10 min
were counted. The control mice afforded 61 stretch reflexes in 10 min.
Hot Plate Tail Flick Activity -Central Analgesic Activity.
C FI male mice (-28g) were administered drugs at 8 mg/kg, I.P., 15 rain prior to placement on a hot plate
ma.intained at 100 C. The time elapse for the tail to be raised from the surface of the hot plate was determined
using a digital read-out connected to the hot plate [23]. The tail flick response of the control mice was 12.12
sec.
Endotoxic Shock Protection.
CFt male mice (-25g) were administered Salmonella lipopolysaccharide (LPS) at 10 mg/kg, IP which is a
dose that is lethal by 100% within 48-52 h [24] Drugs were administered at 8 mg/kg, 2 hr before and 2 hr
after the injection of LPS and every 24 h there after up to 48 h. Deaths were recorded daily for the length of the
study. The percentage deaths at 52 h was calculated and compared to the control value that afforded 16%
survival of the animals at that time.
Table The Hypolipidemic Effects of Boronated Aromatic Amino Acids at 8 mg/kg |.P
Percent of Control (mean +standard deviation)
Serum Cholesterol Serum Triglycerides
N =6 Day 9 Day 16 Day 16
Control 1% CMC 100+5 100+6
b 100+4
1 90+5 90+6 94+6
2 69+5* 61+5’ 63+5*
3 76+4* 74+5* 80+5*
4 75+6* 52+3* 67+5*
5 86+5 69+5* 92+6
6 75+4* 52+3* 92+5
7 71+5’ 68+4* 88+5
8 72+5* 63+4* 61+5"
9 87+6 71+5’ 98+5
10 72+5* 68+6* 55+5*
11 73+4* 67+5* 68+6*
12 73+5* 74+4* 83+5
13 82+6 68+5* 96+6
14 64+3* 55+4* 77+4*
15 68+5* 62+4* 73+4*
16 66+4* 65+6* 78+5*
17 71+7’ 69+5* 65+6*
18 75+3* 68+6* 82+6
19 65+4* 64+5* 82+5
Lovastatin 8 mg/kg 85_+4 82+5 86+7
Clofibrate 150 mg/kg 88+4 78+5 75_+5*
a 125 mg/dL; b 127 mg/dL; c 137 mg/dL.
Enzyme Assays.
CF livers were homogenized in 0.25 M sucrose + 0.001 M EDTA, pH 7.2. Mouse macrophages J774A
were maintained in Dulbecco’s modified medium (DMEM) + 15% fetal calf serum + P/S were homogenized.
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All of the methods for the enzyme studies have been described previously [16]. Acid phosphatase, elastase,
trypsin and cathepsin activities were determined atter 30 min incubation of drugs at 10 M prepared in 1%
CMC at 37C. Acid phosphatase activity was determined using 0.1 M [3-glycerolphosphate in 0.1 M acetate
buffer, pH 5.0. The reaction was stopped with 10% TCA and centrifuged at 3000 x g x 6 min. The
supematant inorganic phosphate was determined by the spectrophotometric method. The net inorganic
phosphate released from 30 min was corrected by subtracting the blank. Cathepsin activity was determined
using 2% azocasein as the substrate in 0.1 M acetate buffer, pH 5.0 and the hydrolyzed acid-soluble peptide
fragment was analyzed at 366 nm and corrected for the blank. Trypsin proteolytic activity was determined by
the method of Schleuning and Fritz [25] using 6 mM N-benzoly-L-arginine ethyl ester (BAEE) in 0.1 M Tris
buffer, pH 8.0. The hydrolyzed product was determined at 253 nm and the blank subtracted. Elastase activity
was determined by the method of Kleinerman et al. [26] with 2 units of porcine pancreatic elastase (Sigma,
Type III), N-succinyl-L-alanyl-L-alanine-p-nitroanilide (Sigma, 100 mg in 5 ml methyl-2-pyrrolidone)in 0.2
M Tris buffer, pH 8.0. The cleaved product p-nitroanilide was determined at 410 nm and the blank
substracted.
Table 2 The Anti-inflammatory Effects of Boronated Aromatic Amino Acids at 8 mg/kg I.P
Percent of Control (mean +standard deviation) N=6
Anti Writhing Hot Plate
-inflammatory -Tail Flick
Control 100+5 100+4 100
8325 77+5* 107
2 90+4 50+4*
3 68_+7* 48+3* 113
4 68+5* 48+_5 139
5 60+5’ 15+:3* 85
6 77+5* 83+4
7 60+6* 97.+_5 83
8 107+6 97+6 120
9 80+5 16+2’
10 63+4* 25+4* 148
11 70+5* 19+3* 218
12 72+4* 21+4’ 131
13 68+3* 15+3’ 189
14 59+__4’ 42+4’ 96
15 76+_4’
16 75+4*
17 70+7* 104+6
18 94+7 94+4
19 70+4+8 83+_4
Standards
Indomethacin 8 mg/kg 74+4* 43+4*
Phenyl-butazone 50 mg/kg 53+4*
Morphine mg/kg 213
Dexamethasone mg/kg
Pentoxifylline 50 mg/kg
LPS
-Protection
16
17
83
100
33
100
100
83
67
83
83
100
100
83
83
67
83
50
67
67
The control values for these assays are located in the Methods section.
RESULTS
The boronated amino acids and their metal complexes demonstrated significant hypolipidemic effects in mice
at 8 mg/kg I.P. [Table 1]. Compounds 6 and 14 caused greater than 40% reduction of total serum cholesterol
levels after 16 days. Compounds 2, 4, 5, 7, 8, 10, 11, 13 and 15-19 afforded greater than 30% reduction of
serum cholesterol after 16 days which was significantly better than the standards clofibrate and lovastatin at
their therapeutic doses. Serum triglycerides were reduced 45% by compound 10. Compounds 2, 6, 8, 11 and
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1’7 lowered serum triglyceride levels greater than 30% which was greater than the standards’ effects. L-
Phenylalanine itself was not active in either assay. The addition of the methyl ester did result in an active
compound indicating that the boron atom was not necessarily important for hypolipidemic activity in mice.
The boronated aromatic amino acid demonstrated anti-inflammatory activity in mice [Table 2] with
compounds 3-5, ’7, 10, 13, 14 and phenylbutazone demonstrating greater than 30% inhibition of edema.
Compounds 6, 11, 12, 15, 16, 1"7, 19 and indomethacin caused greater than 20% reduction. Compounds 2-5,
9-14 and indomethacin afforded at least 50% inhibition of the local analgesic writhing reflex. Central analgesic
activity similar to that demonstrated by morphine at mg/kg with an increase of 113% above the control
value was observed for compounds 11 and 13 which demonstrated increases of 118 % and 89%, respectively at
8 mg/kg. Compounds 4, 8, 10 and 12 demonstrated a significant increase but were not as potent as morphine.
Protection of 100% against LPS induced endotoxin induced shock was afforded by compounds 3, 5, 6, 11 and
12 at 8 mg/kg. Compounds 2, ,7, 9, 10, 13, 14 and 18 caused 83% protection which was better than
compound 8 and 1,7 at 8 mg/kg and dexamethasone at mg/kg and pentoxifylline at 50 mg/kg which caused
67% protection in mice.
The boronated aromatic amino acids in vitro demonstrated the ability to suppress the activities of proteolyic
and lysosomal hydrolytic enzymes in CF mouse liver homogenates and cultured mouse J774A macrophages
[Table 3]. In mouse liver compounds 3-5, ,7, 12-1’7 and 19 afforded greater than 40% inhibition of elastase
activity. Liver cathepsin activity was reduced greater than 30% by compounds 4, 5, ,7, 9 13, 1"7 and 19. Liver
trypsin proteolytic activity was suppressed 94% by compound ,7, but compounds 11-1,7 caused greater than
50% reduction of activity. In the cultured mouse macrophages elastase activity was reduced at least 30% by
compounds 3, 5, 8 10, 12, 15 and 1’7. Macrophage cathepsin activity was inhibited greater than 35% by
compounds 5, 11, 12, 14, 16, 1"7, and 19. Trypsin activity was reduced at least 30% by compounds 10 and
16. Macrophage acid phosphatase activity was reduced 40% by compound 5 and 30% by compound 13.
Table 3 The Effects of Boronated Aromatic Amino Acid on Lysosomal Enzyme Activities
N=4
Control
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Percent of Control (Standard Deviations)
CF Mouse Liver J774A Macrophages.
Elastase Cathepsin Trypsin Elastase Cathepsin Trypsin
100+5 100+4 100+7 100+5 100+6 100+_4
99+4 96+5 97+4 103+5 98+5 102+6
78+_5* 86+6 87+5 73+4* 84+5 92+5
53+3* 75+4* 135+7’ 67+4* 89+6 74+5*
43+4* 65+5* 79+4* 73+4* 113+5 76+5*
48+3* 66+3* 142+5’ 68+.3* 54+3* 82+5
74+4* 75+.3’ 95+5 82+6 74+4* 80+3*
51+4’ 60+4* 6+2* 72+5* 93+_5 94+6
68+_4* 73+5* 81+_4’ 69+_4* 71+5’ 81+5’
73+4* 67+3* 74+4* 78+5* 79+4* 86+4
65+5* 72+4* 117+6 67+6* 89+6 68+5*
60+4* 85+5 30+3* 82+5 57+5* 88+5
59+4* 91+_6 41+4’ 63+4* 61+5’ 90+6
49+3* 66+5* 31+3" 70+5* 72+4* 104+5
54+4* 88+4 38+3* 76+5* 51+4’ 76+5*
55+6* 75+5* 36+2* 69+6* 94+6 84+_6
57+_4* 74_+_3* 44-+/-4* 82+7 57+4* 57+4*
54+3* 68+3* 44+5* 65+6* 62+5* 81+4’
6.+7 71+4’ 62+4* 76+_5* 66+4* 71+.*
58+5* 68+_4* 81+5 96+6 57+_4* 96+5
Acid phosphatase
100+5
97+7
81+4’
76+4*
93+6
60+4*
88+6
97+5
91+4
99+6
95+5
85+5
104+7
70+4*
91+6
103+5
94+4
108+5
90+5
85+_A_4
DISCUSSION
The boronated aromatic peptides demonstrated good hypolipidemic activity that was consistent with other
boronated compounds. They perhaps were more effective in lowering serum cholesterol levels after 16 days
than lowering serum triglycerides levels. (N,N-dimethylmethanamine)dihydro[[[1-(phenyhnethyl)-2-methoxy-
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2-oxoethyl]amino]carbonyl]boron 4 and (cyano)dihydro[[1-(phenylmethyl)-2-amino-2-oxoethyl]amino]boron
14 appear to be the best compounds in this respect and they were markedly more
potent at 8 mg/kg than the standards clofibrate at 150 mg/kg and lovastatin at 8 mg/kg. There did not appear
to significant differences between the phenylalanine, tyrosine, proline, histidine and tryptophan derivatives and
their effects on lowering cholesterol levels. (N,N-dimethymethanamine)dihydro[[[ 1-(4-
hydroxyphenyl)methyl)-2-methoxy-2-oxoethyl]amino]carbonyl]boron 10 was the most potent agent in
lowering serum triglyceride levels on day 16. Again this magnitude of reduction of triglycerides was highly
significant compared to the standard drug effects on this lipid component.
Their anti-inflammatory effects ofthe boronated aromatic amino acids was not as significant as those observed
for the at-amino boranes [16]. The sodium-2-(N,N-dimethylmethanamine)dihydroboron carbonyl)amino-3-
phenylpropanoate 7 (cyano)dihydro[[1-(phenylmethyl)-2-amino-2-oxoethyl]aminoboron 14 achieved the same
degree of reduction of induced edema as the standard phenylbutazone at 50 mg/kg x 2. The agents were better
in reducing local pain [writhing] with (methanamine)dihydro[[[1-(phenylmethyl)-2-methylamino-2-
oxoethyl]amino]carbonyl]boron 5 as well as the tyrosine derivatives 9-13 affording better activity than the
standard indomethacin. The other boronated aromatic amino acids were not significantly active in reducing
local pain. (N-methylmethanamide)dihydro[[[1-(4-hydroxyphenylmethyl)-2-methoxy-2-oxoethyl
]amino]carbonyl]boron 11 was the only compound that was as active as morphine in reducing central pain
although compound 13 was significantly effective. The phenylalanine derivatives did not demonstrate any
ability to block central pain. The boronated aromatic acids did protect the mouse from LPS induced shock
and many of the tested derivatives were more potent than the standards dexamethasone and pentoxifylline at
their therapeutic doses. Those compounds without a boron atom, compounds 1 and 2 offered no protection
against LPS induced shock. Previously amine-carboxyboranes were shown to inhibit proteolytic and
lysosomal hydrolytic enzyme activities [16]. The present study would suggest that similar mechanisms of
action are caused by the boronated aromatic amino acids for their anti-inflammatory activity. The amine-
carboxyboranes also suppressed prostaglandin synthetase and cytokine, e.g. II-1 and TNF release as well as
the migration of white cells to the inflammation site [16]. Whereas further investigation of this group of
compounds is required, they may offer some therapeutic use in the future because of the low dose required for
their in vivo activity as hypolipidemic and anti-inflammatory agents.
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